Table 1.

Profile of the patients

Control									With TNF inhibitors
Age	Gender	Disease duration	Class	Treatment	Ope	CRP	DAS28	X-p stage	Age	Gender	Disease duration	Class	Treatment	Ope	CRP	DAS	X-p stage
72	F	25	4	Tac	TAA	3.00	5.33	4	49	M	21	4	Eta, Tac, PSL	THA	4.40	4.92	3
67	F	17	4	MTX	THA	1.10	4.04	3	52	F	28	3	Eta, MTX	TKA	1.70	5.11	4
43	F	22	4	PSL	THA	1.24	4.56	4	41	F	19	3	Eta, MTX	TKA	0.30	4.13	4
60	F	17	3	(–)	TKA	0.46	3.59	3	45	F	12	3	Eta, Tac, PSL, MTX	TEA	0.57	3.75	3
59	M	10	3	PSL, MTX	TKA	1.41	4.54	4	50	M	7	4	Inf, Tac, PSL, MTX	THA	0.17	2.95	3
51	F	18	2	PSL, Tac	FoAp	3.90	5.23	3	66	F	22	3	Eta, PSL	TKA	0.44	3.67	4
59	F	19	4	PSL, MTX, Tac, BUC	TKA TEA	0.34	3.87	4	33	F	8	2	Eta, PSL, MTX	WAp	0.67	4.4	3
55	F	38	3	Tac, MTX	TKA	0.31	3.21	4	30	F	18	2	Eta, PSL, MTX, Tac	ESy	1.23	3.86	4
71	F	18	4	PSL, MTX	TKA	0.30	3.69	3	56	F	19	3	Inf, PSL, MTX	TEA	2.95	4.88	4
62	F	38	2	PSL, SASP	FiAp	0.04	2.97	4	62	F	23	3	Inf, PSL, Tac, MTX	TKA	7.16	6.22	3
38	F	17	3	PSL, SASP, MTX	TKA	0.80	3.78	3	51	F	10	4	Eta, PSL, SASP, MTX	THA	0.63	4.13	3
63	F	21	3	SASP	TKA	1.80	3.62	3	53	F	13	2	Eta, PSL, BUC, MTX	FoAp	0.68	4.78	4
Mean		21.7				1.23	4.04		Mean		16.7				1.74	4.40

PSL prednisolone, MTX Mthotrexate, BUC Bucillamine, Tac Tacrolimus, SASP Sulfasalazopyridine, Eta etanercept, Inf infliximab, TAA total ankle arthroplasty, THA total hip arthroplasty, TKA total knee arthroplasty, TEA total elbow arthroplasty, FoAp foot athroplasty, FiAp finger arthroplasty, WAp wrist arthroplasty, ESy elbow synovectomy